Ever-expanding Japanese beverage behemoth, Suntory, is the new owner of Lucozade and Ribena, which GlaxoSmithKline (GSK) has sold for £1.35bn (€1.6bn/$2.11bn) as it admits defeat in its internationalisation plans and trains its focus on its pharma activities.
Sources close to GlaxoSmithKline have confirmed that the sale of its iconic Lucozade and Ribena brands to expanding Japanese beverage giant, Suntory, will proceed for a sum closer to initial estimations of £1bn (€1.18bn/$1.55bn), but an industry analyst...
Reports suggest UK soft drinks firm AG Barr could mount a £1bn+ bid for GlaxoSmithKline (GSK) brands Lucozade and Ribena, with support from private equity.
GlaxoSmithKline’s (GSK’s) brands Lucozade and Ribena are tempting targets for Far Eastern trade players such as Suntory Holdings that wish to establish a bridgehead in the UK, says an M&A expert.
DISPATCHES FROM THE 2013 INNOBEV GLOBAL BEVERAGES CONGRESS, WARSAW, POLAND
GSK brand Lucozade is more likely to attract a possible private equity buyer than a multinational food and beverage trade player that prefers brands with greater global potential, according to a top M&A expert.
GlaxoSmithKline (GSK) has launched a strategic review of its Lucozade and Ribena brands, hinting that the western-facing brands do not fit its increased focus on emerging markets such as China and India.
GlaxoSmithKline's Plenty juice drink brand is to be relaunched six
months after it was withdrawn. Market analysts Datamonitor assess
the product's chances of success.